Fluoxetine and sertraline attenuate postischemic brain injury in mice

Korean Journal of Physiology and Pharmacology

Volumn 13, Issue 3, 2009, Pages 257-263

  Tae, Kyeong Shin ^a   Mi, Sun Kang ^a   Ho, Youn Lee ^a   Moo, Sang Seo ^a   Si, Geun Kim ^a   Chi, Dae Kim ^a   Won, Suk Lee ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Cerebral blood flow autoregulation; Focal cerebral ischemia; Heme oxygenase 1; Hypoxia inducible factor 1 ; Selective serotonin reuptake inhibitors

Indexed keywords

FLUOXETINE; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SERTRALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOREGULATION; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FRONTAL CORTEX; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SOMATOSENSORY CORTEX;

EID: 67651015248     PISSN: 12264512     EISSN: None     Source Type: Journal    
DOI: 10.4196/kjpp.2009.13.3.257     Document Type: Article

References (58)

1. Acker T, Acker H. Cellular oxygen sensing need in CNS function: physiological and pathological implications. J Exp Biol 207: 3171-3188, 2004. (Pubitemid 39275292)
2. Andersen G, Vestergaard K, Riis J, Lauritzen L. Incidence of post-stroke depression during the first year in a large unselected stroke population determined using a valid standardized rating scale. Acta Psychiatr Scand 90: 190-195, 1994b. (Pubitemid 24291618)
3. Arboix A, Garcia-Eroles L, Comes E, Oliveres M, Balcells M, Pacheco G, Targa C. Predicting spontaneous early neurological recovery after acute ischemic stroke. Eur J Neurol 10: 429-435, 2003. (Pubitemid 41754764)
4. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17: 1304-1308, 1986.
5. Betz AL. Vasogenic brain edema. In: Welch KMA, Caplan LR, Reis DJ, Siesj BK, Weir B, ed, Primer on cerebrovascular diseases. San Diego: Academic Press, p 56-159, 1997.
6. Bhardwaj A, Alkayed NJ, Kirsch JR, Hurn PD. Mechanisms of ischemic brain damage. Curr Cardiol Rep 5: 160-167, 2003.
7. Bhogal SK, Teasell R, Foley N, Speechley M. Heterocyclics and selective serotonin reuptake inhibitors in the treatment and prevention of post-stroke depression. J Am Geriatr Soc 53: 1051-1057, 2005. (Pubitemid 41647607)
8. Bidmon HJ, Emde B, Oermann E, Kubitz R, Witte OW, Zilles K. Heme oxygenase-1 (HSP-32) and heme oxygenase-2 induction in neurons and glial cells of cerebral regions and its relation to iron accumulation after focal cortical photothrombosis. Exp Neurol 168: 1-22, 2001. (Pubitemid 32195254)
9. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15: 220-226, 1994. (Pubitemid 24210726)
10. Bonne O, Krausz Y, Gorfine M, Karger H, Gelfin Y, Shapira B, Chisin R, Lerer B. Cerebral hypoperfusion in medication resistant, depressed patients assessed by Tc99m HMPAO SPECT. J Affect Disord 41: 163-171, 1996. (Pubitemid 26422946)
11. Bonvento G, MacKenzie ET, Edvinsson L. Serotonergic innervation of the cerebral vasculature: relevance to migraine and ischaemia. Brain Res Brain Res Rev 16: 257-263, 1991.
12. Chiou SH, Chen SJ, Peng CH, Chang YL, Ku HH, Hsu WM, Ho LL, Lee CH. Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell. Biochem Biophys Res Commun 343: 391-400, 2006.
13. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, Freo U, Piron L, Battistin L. Effects of fluoxetine and maprotiline on functional recovery in post-stroke hemiplegic patients undergoing rehabilitation therapy. Stroke 27: 1211-1214, 1996. (Pubitemid 26226957)
14. Dawn B, Bolli R. HO-1 induction by HIF-1: a new mechanism for delayed cardioprotection? Am J Physiol Heart Circ Physiol 289: H522-H524, 2005.
15. Demougeot C, Van Hoecke M, Bertrand N, Prigent-Tessier A. Mossiat C, Beley A, Marie C. Cytoprotective efficacy and mechanisms of the liposoluble iron chelator 2,2′-dipyridyl in the rat photothrombotic ischemic stroke model. J Pharmacol Exp Ther 311: 1080-1087, 2004. (Pubitemid 39612714)
16. Dijkhuizen RM, Ren J, Mandeville JB, Wu O, Ozdag FM, Moskowitz MA, Rosen BR, Finklestein SP. Functional magnetic resonance imaging of reorganization in rat brain after stroke. Proc Natl Acad Sci U S A 98: 12766-12771, 2001.
17. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 54: 597-606, 1997.
18. Fu R, Zhao ZQ, Zhao HY, Zhao JS, Zhu XL. Expression of heme oxygenase-1 protein and messenger RNA in permanent cerebral ischemia in rats. Neurol Res 28: 38-45, 2006. (Pubitemid 43204490)
19. Gainotti G, Antonucci G, Marra C, Paolucci S. Relation between depression after stroke, antidepressant therapy, and functional recovery. J Neurol Neurosurg Psychiatry 71: 258-261, 2001. (Pubitemid 32675158)
20. Geddes JW, Pettigrew LC, Holtz ML, Craddock SD, Maines MD. Permanent focal and transient global cerebral ischemia increase glial and neuronal expression of heme oxygenase-1, but not heme oxygenase-2 protein in rat brain. Neurosci Lett 210: 205-208, 1996.
21. 1A receptor-mediated hypothermia and serotonin syndrome produced by 8-OH-DPAT in the rat. Psychopharmacology 91: 500-505, 1987.
22. Hanlon CA, Burlington AL, McKeown MJ. New brain networks are active after right MCA stroke when moving the ipsilesional arm. Neurology 64: 114-120, 2005.
23. Harukuni I, Bhardwaj A. Mechanisms of brain injury after global cerebral ischemia. Neurol Clin 24: 1-21, 2006. (Pubitemid 43144627)
24. Hensler JG, Kovachich GB, Frazer A. A quantitative autoradiographic study of serotonin1A receptor regulation. Effect of 5,7-dihydroxytryptamine and antidepressant treatments. Neuropsychopharmacology 4: 131-144, 1991.
25. Ishii H, Bertrand N, Stanimirovic D, Strasser A, Mrsulja BB, Spatz M. The relationship between cerebral ischemic edema and monoamines: revisited. Acta Neurochir Suppl (Wien) 60: 238-241, 1994.
26. Jakovljevic D, Tuomilehto J. Use of selective serotonin reuptake inhibitors and the risk of stroke: is there reason for concern? Stroke 33: 1448-1449, 2002.
27. Kim JS, Choi S, Kwon SU, Seo YS. Inability to control anger or aggression after stroke. Neurology 58: 1106-1108, 2002. (Pubitemid 34298556)
28. Kotila M, Numminen H, Waltimo O, Kaste M. Post-stroke depression and functional recovery in a population-based stroke register. The Finnstroke study. Eur J Neurol 6: 309-312, 1999. (Pubitemid 29250990)
29. Kreiss DS, Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine. J Pharmacol Exp Ther 274: 866-867, 1995.
30. 1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 39: 110-122, 2000.
31. Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, Choi AM. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 272: 5371-5381, 1997. (Pubitemid 27102353)
32. 1A agonist. J Pharmacol Exp Ther 279: 1035-1042, 1996. (Pubitemid 27166882)
33. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 37: 517-554, 1997.
34. Malberg JE. Implications of adult hippocampal neurogenesis in antidepressant action. J Psychiatry Neurosci 29: 196-205, 2004. (Pubitemid 38829856)
35. Marks GS, Brien JF, Nakatsu K, McLaughlin BE. Does carbon monoxide have a physiological function? Trends Pharmacol Sci 12: 185-188, 1991.
36. Muhonen MG, Robertson SC, Gerdes JS, Loftus CM. Effects of serotonin on cerebral circulation after middle cerebral artery occlusion. J Neurosurg 87: 301-306, 1997. (Pubitemid 27349118)
37. Nakayama H, Jorgensen HS, Raaschou HO, Olsen TS. The influence of age on stroke outcome. The Copenhagen Stroke Study. Stroke 25: 808-813, 1994.
38. Nimura T, Weinstein PR, Massa SM, Panter S, Sharp FR. Heme oxygenase-1 (HO-1) protein induction in rat brain following focal ischemia. Brain Res Mol Brain Res 37: 201-208, 1996. (Pubitemid 26147991)
39. Otterbein LE, Choi AM. Heme oxygenase: colors of defense against cellular stress. Am J Physiol Lung Cell Mol Physiol 279: L1029-L1037, 2000.
40. Panahian N, Yoshiura M, Maines MD. Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. J Neurochem 72: 1187-1203, 1999. (Pubitemid 29085035)
41. Paolucci S, Antonucci G, Grasso MG, Morelli D, Troisi E, Coiro P, De Angelis D, Rizzi F, Bragoni M. Post-stroke depression, anti-depressant treatment and rehabilitation results. A case-control study. Cerebrovasc Dis 12: 264-271, 2001.
42. Parikh RM, Robinson RG, Lipsey JR, Starkstein SE, Fedoroff JP, Price TR. The impact of post-stroke depression on recovery in activities of daily living over a 2-year follow-up. Arch Neurol 47: 785-789, 1990.
43. Primeau F. Post-stroke depression: a critical review of the literature. Can J Psychiatry 33: 757-765, 1988. (Pubitemid 18279785)
44. Pulsinelli WA. Selective neuronal vulnerability: morphological and molecular characteristics. Prog Brain Res 63: 29-37, 1985.
45. Ramasubbu R, Patten SB. Effect of depression on stroke morbidity and mortality. Can J Psychiatry 48: 250-257, 2003. (Pubitemid 36733832)
46. Rampello L, Bartaglia G, Raffaele R, Vecchio I, Alvano A. Is it safe to use antidepressants after a stroke? Expert Opin Drug Saf 4: 885-897, 2005.
47. Rasmussen A, Lunde M, Poulsen DL, Sørensen K, Qvitzau S, Bech P. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 44: 216-221, 2003. (Pubitemid 36514728)
48. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, Curdue K, Petracca G, Starkstein SE. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 157: 351-359, 2000. (Pubitemid 30145919)
49. Ryter SW, Otterbein LE, Morse D, Choi AM. Heme oxygenase/carbon monoxide signaling pathways: regulation and functional significance. Mol Cell Biochem 234-235: 249-263, 2002. (Pubitemid 34777864)
50. Sanchez V, Camarero J, Esteban B, Peter MJ, Green AR, Colado MI. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. Br J Pharmacol 134: 46-57, 2001. (Pubitemid 32835467)
51. Schroeter M, Jander S, Stoll G. Non-invasive induction of focal cerebral ischemia in mice by photothrombosis of cortical microvessels: characterization of inflammatory responses. J Neurosci Methods 117: 43-49, 2002. (Pubitemid 34663898)
52. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 7: 345-350, 2001. (Pubitemid 32735019)
53. Semenza GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 106: 809-812, 2000.
54. Starkstein SE, Robinson RG. Affective disorders and cerebral vascular disease. Br J Psychiatry 154: 170-182, 1989.
55. 2+ channel opener. Stroke 30: 1949-1954, 1999.
56. Uyama O, Okamura N, Yanase M, Narita M, Kawabata K, Sugita M. Quantitative evaluation of vascular permeability in the gerbil brain after transient ischemia using Evans blue fluorescence. J Cereb Blood Flow Metab 8: 282-284, 1988. (Pubitemid 18079698)
57. Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH. Carbon monoxide: a putative neural messenger. Science 259: 381-384, 1993. (Pubitemid 23982390)
58. Welch KM, Chabi E, Buckingham J, Bergin B, Achar VS, Meyer JS. Cathecholamine and 5-hydroxytryptamine levels in ischemic brain. Influence of p-chlorophenylalanine. Stroke 8: 341-346, 1977.